Brokerages Set Aemetis, Inc. (NASDAQ:AMTX) Target Price at $12.95

Shares of Aemetis, Inc. (NASDAQ:AMTX) have been given a consensus rating of “Moderate Buy” by the five brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $12.95.

Several research analysts have recently issued reports on AMTX shares. StockNews.com upgraded shares of Aemetis to a “sell” rating in a report on Friday, January 3rd. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Aemetis in a report on Monday, December 23rd.

Aemetis Stock Up 1.8 %

NASDAQ AMTX opened at $2.87 on Monday. The firm has a 50 day moving average of $3.28 and a two-hundred day moving average of $2.97. Aemetis has a 52 week low of $2.10 and a 52 week high of $7.03. The stock has a market capitalization of $142.74 million, a PE ratio of -1.27 and a beta of 1.47.

Aemetis (NASDAQ:AMTX) last issued its earnings results on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.09. The company had revenue of $81.44 million during the quarter, compared to analyst estimates of $77.79 million. During the same quarter in the previous year, the company posted ($0.59) EPS. On average, equities research analysts expect that Aemetis will post -2.02 earnings per share for the current fiscal year.

Institutional Trading of Aemetis

Institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC raised its position in Aemetis by 68.2% during the 3rd quarter. FMR LLC now owns 22,531 shares of the specialty chemicals company’s stock worth $52,000 after buying an additional 9,137 shares during the last quarter. Hutchinson Capital Management CA purchased a new position in Aemetis during the 2nd quarter worth $70,000. Barclays PLC raised its position in Aemetis by 274.6% during the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock worth $109,000 after buying an additional 34,816 shares during the last quarter. Rhumbline Advisers raised its position in Aemetis by 2,837.1% during the 2nd quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock worth $157,000 after buying an additional 50,528 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in Aemetis during the 3rd quarter worth $177,000. Hedge funds and other institutional investors own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.